Commentary on Abstract #2003

Publication
Article
OncologyONCOLOGY Vol 13 No 3
Volume 13
Issue 3

The role of interferon-alfa (Intron A, Roferon) in the management of patients with low-grade NHL remains controversial. More than 10 randomized trials have been reported.

The role of interferon-alfa (Intron A, Roferon) in the management of patients with low-grade NHL remains controversial. More than 10 randomized trials have been reported.

A recent meta-analysis concluded that interferon appeared to afford a benefit with regard to progression-free and overall survival, but only when it was used in combination with aggressive chemotherapy (Rohatiner et al: Proc Am Soc Clin Oncol 17:4a[abstract 11], 1998). However, this meta-analysis did not include a large negative Southwest Oncology Group (SWOG) trial (Dana et al: Proc Am Soc Clin Oncol 17:3a[abstract 10], 1998).

One of the most notable interferon trials, conducted by the GELA group (Solal-Céligny et al: J Clin Oncol 16:2332-2338, 1998), led to the FDA approval of interferon in combination with an anthracycline regimen for indolent NHL. Coiffier and coworkers conducted a subsequent trial based on these data, which was presented at the ASH meeting (abstract #2003). Elderly patients with low-grade NHL were randomized to CHVP (cyclophosphamide, doxurubicin, VP-26, and prednisone) plus interferon or fludarabine. The response rate, time to progression, and survival favored the multiagent arm. However, as noted above, there are now fludarabine-based combinations that appear to be more effective than the single agent, and one of these would be a reasonable arm for a similar comparative trial. Moreover, recent enthusiasm for new monoclonal antibodies will likely replace interest in the interferon-based regimens.

Articles in this issue

WHO Declares Lymphatic Mapping to Be the Standard of Care for Melanoma
Rituximab: Phase II Retreatment Study in Patients With Low-Grade or Follicular Non-Hodgkin’s Lymphoma
Response Criteria for NHL: Importance of “Normal” Lymph Node Size and Correlations With Response
Chemotherapy Plus Radiation Improves Survival in Patients With Cervical Cancer
A Randomized Trial of Fludarabine, Mitoxantrone (FM) Versus Doxorubicin, Cyclophosphamide, Vindesine, Prednisone (CHEP) as First Line Treatment in Patients With Advanced Low-Grade Non-Hodgkin's Lymphoma: A Multicenter Study by GOELAMS Group
Navelbine Increased Elderly Lung Cancer Patients’ Survival
Fludarabine Versus Conventional CVP Chemotherapy in Newly C Diagnosed Patients With Stages III and IV Low-Grade Malignant Non-Hodgkin’s Lymphoma: Preliminary Results From a Prospective, Randomized Phase III Clinical Trial in 381 Patients
Multicenter, Phase III Study of Iodine-131 Tositumomab (Anti-B1 Antibody) for Chemotherapy-Refractory Low-Grade or Transformed Low-Grade Non-Hodgkin’s Lymphoma
T-Cell–Depleted Allogeneic Bone Marrow Transplant From HLA-Matched Sibling Donors for Non-Hodgkin’s Lymphoma
Consensus Statement on Prevention and Early Diagnosis of Lung Cancer
In Vivo Purging and Adjuvant Immunotherapy With Rituximab During PBSC Transplant For NHL
Fludarabine and Cyclophosphamide: A Highly Active and Well-Tolerated Regimen for Patients With Previously Untreated Indolent Lymphomas
Campath-1H Monoclonal Antibody in Therapy for Advanced Low-Grade Non-Hodgkin’s Lymphomas: A Phase II Study
AIDS Drugs Effective Against Most Common HIV Strain
Rituximab Therapy in Previously Treated Waldenström’s Macroglobulinemia: Preliminary Evidence of Activity
Related Videos
Although no responses were observed in 11 patients receiving abemaciclib monotherapy, combination therapies with abemaciclib may offer clinical benefit.
Stacey A. Cohen, MD, and Daniel H. Ahn, DO, presenting slides
Stacey A. Cohen, MD, and Daniel H. Ahn, DO, presenting slides
Findings show no difference in overall survival between various treatments for metastatic RCC previously managed with immunotherapy and TKIs.
An epigenomic profiling approach may help pick up the entire tumor burden, thereby assisting with detecting sarcomatoid features in those with RCC.
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
Cesar Rodriguez, MD, and Frits van Rhee, MD, PhD
Investigators are assessing the use of IORT in patients with borderline resectable or unresectable pancreatic cancer as part of the phase 2 PACER trial.
4 KOLs are featured in this panel.
Related Content